11
Participants
Start Date
March 10, 2017
Primary Completion Date
October 1, 2020
Study Completion Date
January 13, 2021
Atezolizumab
Given IV
Bevacizumab
Given IV
Laboratory Biomarker Analysis
Correlative studies
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
University of Virginia Cancer Center, Charlottesville
Virginia Commonwealth University/Massey Cancer Center, Richmond
Emory University Hospital Midtown, Atlanta
Emory University Hospital/Winship Cancer Institute, Atlanta
Moffitt Cancer Center, Tampa
University of Kentucky/Markey Cancer Center, Lexington
Ohio State University Comprehensive Cancer Center, Columbus
University of Wisconsin Hospital and Clinics, Madison
M D Anderson Cancer Center, Houston
University of Colorado Hospital, Aurora
Los Angeles County-USC Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
Keck Medical Center of USC Pasadena, Pasadena
Massachusetts General Hospital Cancer Center, Boston
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH